Ascentage Pharma, IPO
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
Venture Global launched its initial public offering with a lofty goal: Raise up to $2.3 billion at a $110 billion valuation ...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
According to market observers, shares of the company are available at a premium of ₹151 in the grey market today ...
When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback